Alexion: New formulation of ULTOMIRIS® in Europe
Alexion Pharmaceuticals reports that the European Commission has approved the new 100 mg/mL intravenous formulation of ULTOMIRIS® (ravulizumab) for the treatment of two ultra-rare diseases:...
Home >
Access the latest news, business developments, company updates, industry trends, events and more.
Alexion Pharmaceuticals reports that the European Commission has approved the new 100 mg/mL intravenous formulation of ULTOMIRIS® (ravulizumab) for the treatment of two ultra-rare diseases:...
It is our pleasure to welcome Strategic Spaces|DIRTT as BioCT’s newest Sponsor and Partner. A leader in the life science space, with offices in Hartford and Boston, Strategic...
BioPath – an SCSU-led partnership of industry, academic and government leaders — has announced several new programs designed to meet the workforce needs of Connecticut’s growing bioscience...
Sema4 has opened its second state-of-the-art clinical laboratory in Connecticut. The newly built 70,000 square foot facility in Stamford will be home to 300+ employees and...
Deloitte has released its “North America Technology Fast 500,” an annual ranking of the fastest-growing North American companies in the technology, media, telecommunications, life sciences, fintech...
U.S. Senator Chris Murphy (D-Conn.) has named Azitra Inc. in Branford Innovator of the Month. The company currently has 14 employees in Connecticut and will be...
The drugmaker Moderna said it is applying to the FDA to authorize its coronavirus vaccine for emergency use. The first injections may be given as...
A team of researchers at UConn are working on ways to reverse the effects of aging, as a way to mitigate the severity of a...
Woven Orthopedic Technologies, based in Manchester, is bringing its surgical screw sleeves, in development since 2013, to the U.S. market. The FDA granted a so-called...
Bristol-Myers Squibb has successfully completed its acquisition of MyoKardia in an all cash transaction for approximately $13.1 billion. “We are excited to welcome MyoKardia colleagues...